Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood ...

Molina, MDMedically reviewed by Jurairat J. Molina, MD COVID-19 and the COVID vaccine can affect red blood cell count, ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line ...

Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess ...

and polycythemia vera (PV) after long-term treatment (>12 months). IFN-α2 induces sustained major or complete molecular remissions in a subset of PV patients with normalization of the bone marrow ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and polycythemia vera must be excluded. The present case and others in the literature indicate that the ...

Just like any chronic health condition, polycythemia vera (PV) can have a negative impact on your everyday life. Research has shown that PV is associated with a lower quality of life in measures ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...